How Good Is Wegovy’s Heart Benefit? — Experts put SELECT trial findings in context

MedPage Today, August 1, 2024: When the company that makes Wegovy weight loss drugs say it reduces major cardiovascular events by 20% they really mean it reduces that risk by 1.5% for each patient. That’s because only 8% of the placebo group had major cardiovascular events, compared to 6.5% of the Wegovy patients. Isn’t that misleading? We explain why most weight loss patients will not benefit in terms of heart disease, because the benefit is small and requires staying on Wegovy for almost 3 years.

Read More »